Senphonix Receives National Institutes of Health Grant to Advance SleeveSense, a Continuous, Long-Term Vitals Monitoring Platform

Source: BioSpace, written by Annalee Armstrong (October 14, 2026). AI-generated summary by biochip.com, published October 14, 2026. Not independently reviewed.

Senphonix has received a Small Business Innovation Research Phase I award from the National Institutes of Health's National Heart, Lung, and Blood Institute to advance the software and data infrastructure behind its SleeveSense wearable. The upper-arm sleeve is being developed to collect vital signs continuously over extended periods, rather than relying on periodic manual checks in hospitals and at home. The funding supports clinical-environment software testing, cloud and database scaling, and cybersecurity work as the company prepares for clinical evaluation and eventual regulatory review.

Funding Targets the Data Platform

The National Institutes of Health, or NIH, award is Senphonix's second federal research grant announced within weeks. In September, the company announced a National Science Foundation Small Business Technology Transfer Phase I award intended to support SleeveSense wireless hardware and software-platform development.

The new NIH funding specifically focuses on the system that handles information after the wearable collects it. Senphonix plans to test its software stack, meaning the connected layers of applications, databases, and cloud services that move patient measurements to care teams. The company also plans cybersecurity work toward SOC 2 Type II readiness, a commonly used framework for assessing controls around sensitive data.

A Sleeve Built for Continuous Monitoring

SleeveSense is designed as an upper-arm wearable that patients could wear continuously for days, weeks, or months. Senphonix says the device is intended to work across hospital, outpatient, and at-home settings, with wireless charging so users would not need to remove it to recharge.

The company is targeting clinical-grade measurements, but has not yet established that performance. Senphonix plans to validate accuracy in upcoming clinical testing, and it says the device remains in development rather than cleared or approved by the U.S. Food and Drug Administration.

Addressing Gaps Between Vital-Sign Checks

Manual vital-sign checks provide snapshots rather than a continuous record. Senphonix argues that this approach can take nurses away from direct patient care and may miss changes that occur between scheduled measurements. Continuous monitoring works more like a security camera than occasional photographs: it aims to provide a running view of a patient's condition rather than isolated readings.

The company plans to make SleeveSense data available to clinicians through the electronic health record during a hospital stay and after discharge. Patients would also be able to view their vital signs through a mobile app, according to Senphonix.

Commercial and Clinical Plans

Senphonix says it intends to provide and manage the supporting infrastructure, billing hospitals only when a sleeve is assigned to a patient. The company also reported surveys commissioned by Senphonix in which 98 percent of 402 nurses and 94 percent of 457 health care chief financial officers said they would support adoption within their organizations.

Those surveys were administered by MarketWise Advising, whose founder and president, Mike Haldane, is also Senphonix's co-founder and co-chief executive officer. The findings indicate stated interest, not clinical effectiveness, purchasing commitments, or deployment by health systems.

Why This Matters

Wearable sensors alone do not automatically fit into clinical practice. A usable monitoring system also needs secure data handling, integration with clinicians' existing records, reliable infrastructure, and evidence that its measurements perform accurately in real settings. The NIH award funds parts of that operational foundation while the company works toward clinical validation.

Senphonix expects to begin a clinical study in late 2026 or early 2027 and intends to seek FDA 510(k) clearance in early to mid-2027 after clinical testing. The next important evidence will be whether SleeveSense can deliver the accuracy, comfort, and workflow fit that its design targets promise.

Start here: What is a biochip?